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Abstract
Background: The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is low,
prompting interest in targeted molecular therapies. We investigated HER2 expression and
amplification, and the potential for trastuzumab therapy in this histologic subtype of ovarian cancer.
Methods: HER2 status was tested in 33 mucinous carcinomas and 16 mucinous borderline ovarian
tumors (BOT)). Five cases with documented recurrence and with tissue from the recurrence
available for testing were analyzed to determine whether HER2 amplification status changed over
time. Three prospectively identified recurrent mucinous ovarian carcinomas were assessed for
HER2 amplification and patients received trastuzumab therapy with conventional chemotherapy.
Results: Amplification of HER2 was observed in 6/33 (18.2%) mucinous carcinomas and 3/16
(18.8%) BOT. HER2 amplification in primary mucinous carcinomas was not associated with an
increased likelihood of recurrence. The prospectively identified recurrent mucinous carcinomas
showed overexpression and amplification of HER2; one patient's tumor responded dramatically to
trastuzumab in combination with conventional chemotherapy, while another patient experienced
an isolated central nervous system recurrence after trastuzumab therapy.
Conclusion: HER2 amplification is relatively common in ovarian mucinous carcinomas (6/33,
18.2%), although not of prognostic significance. Trastuzumab therapy is a treatment option for
patients with mucinous carcinoma when the tumor has HER2 amplification and overexpression.
Published: 10 December 2009
BMC Cancer 2009, 9:433 doi:10.1186/1471-2407-9-433
Received: 12 March 2009
Accepted: 10 December 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/433
© 2009 McAlpine et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:433 http://www.biomedcentral.com/1471-2407/9/433
Page 2 of 12
(page number not for citation purposes)
Background
The majority of ovarian mucinous tumors are borderline
tumors or stage I carcinomas, and the prognosis, overall,
for patients with early stage mucinous carcinoma is excel-
lent. The prognosis in patients with spread beyond the
ovaries, however, is extremely poor. Chemotherapy with
paclitaxel and carboplatin is recommended for patients
with metastatic mucinous carcinoma, but response rates
are considerably lower than are observed in other sub-
types of epithelial ovarian cancer (EOC) [1-6]. At present
no superior alternative treatment options exist.
HER2 is a member of the epidermal growth factor family
of tyrosine kinase receptors. Activation of HER2 triggers a
cascade of cellular responses, impacting cellular prolifera-
tion, angiogenesis and metastasis [7-9]. Amplification
and overexpression of HER2 is seen in approximately
15% of breast carcinomas and is associated with a poor
prognosis [10-14]. Adjuvant therapy using a monoclonal
antibody against HER2 protein (trastuzumab) is effective
alone and in combination with conventional cytotoxic
chemotherapy in patients whose breast carcinomas have
amplification of HER2 [15-18]. In contrast, the signifi-
cance of HER2 overexpression and amplification in EOC
is less well understood. The reported frequency of HER2
overexpression in EOC ranges from 5-66% [19-23],
although more recent studies using validated techniques
for detection of HER2 overexpression or amplification
have consistently shown results at the low end of this
range [21,22]. Clinical response to single agent trastuzu-
mab in EOC has been disappointing. In a series of 41
patients with HER2 overexpressing EOC, identified from
a series of 837 EOC tested for HER2 expression, there was
only one complete responder and two partial responders
for an overall response rate of 7.3% and a median progres-
sion-free interval of two months [19]. In this series, HER2
expression was determined by immunohistochemistry
(IHC) only, and none of the patients in this series had car-
cinomas of mucinous subtype.
There has been an increasing appreciation of the molecu-
lar differences between the different histologic subtypes of
EOC [24-26]. Differences in initial presentation, metasta-
sis, response to therapy, and overall prognosis have been
described and there has been criticism of the conventional
approach of treating EOC as one entity [27]. Most series
analyzing HER2 expression in EOC have not performed
subtype analysis based on histology and often have poor
or absent representation of mucinous carcinoma
[19,20,22,23,28].
Given the absence of data on mucinous ovarian tumors
and HER2 expression, inference may be permitted based
on histological and immunohistochemical similarities
between mucinous ovarian tumors and tumors of the
upper gastrointestinal tract [29-31]. Activity of trastuzu-
mab has been demonstrated in preclinical models of gas-
tric and esophageal cancers [32-35]; approximately 7-15%
of gastroesophageal adenocarcinomas show amplifica-
tion of HER2. This prompted our investigation of HER2
expression in patients with recurrent mucinous EOC. Our
objectives in this study were 1) to look for HER2 protein
overexpression (IHC) and gene amplification (FISH) in
our current and a historical patient population of patients
with mucinous EOC and mucinous borderline ovarian
tumors (BOT), 2) examine the correlation between HER2
immunostaining and amplification, 3) determine if HER2
expression or amplification status changed from the time
of initial presentation to recurrence, 4) treat patients with
recurrent mucinous ovarian carcinoma with trastuzumab,
when the tumor has HER2 amplification and overexpres-
sion, and monitor for response to treatment.
Methods
Case Selection
Following Institutional Review Board approval the fol-
lowing cases were identified: 1) a cohort of 34 cases of
mucinous carcinoma from 1984-2000 in British Colum-
bia (BC); these were identified as part of a population-
based review of cases of ovarian carcinoma who had no
microscopic residual disease after primary surgery. This
cohort has been described previously [36] and the 34
mucinous carcinomas are part of a tissue microarray con-
sisting of 541 cases of ovarian cancer, 2) three mucinous
carcinomas and seven mucinous BOT collected as part of
our Ovarian Tumor Bank in BC, since 2000, 3) three archi-
val cases from a previously published series on mucinous
ovarian carcinomas from our institution [37], and 4) 15
mucinous BOT cases, gastrointestinal type, from the
pathology archives of Johns Hopkins University School of
Medicine collected from their institution (n = 12) or as
consults from other institutions (n = 3) during the period
between 1994-2005. Three patients with recurrent muci-
nous carcinoma and HER2 amplification were treated
with a combination of HER2 targeted therapy (trastuzu-
mab) and platin-based chemotherapy and followed pro-
spectively. Response was based on serial examinations,
tumor markers, and CT imaging (RECIST criteria) and
written informed consent was obtained for publication of
associated text and images. A copy of the written consent
is available for review by the Editor-in-Chief of this jour-
nal.
Immunohistochemistry
IHC was performed on either whole sections, or for the
retrospective, population based series, on tissue microar-
ray slides in which duplicate 0.6 mm cores from each case
were present in the array. Four micron thick sections were
immunostained on a Ventana Benchmark XT staining sys-
tem (Ventana Medical Systems, Tucson, AZ, USA). Sec-
tions were deparaffinized in xylene, dehydrated through
three alcohol changes and transferred to Ventana WashBMC Cancer 2009, 9:433 http://www.biomedcentral.com/1471-2407/9/433
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solution. Heat antigen retrieval was used. Endogenous
peroxidase activity was blocked in 3% hydrogen peroxide.
Slides were then incubated with rabbit monoclonal anti-
HER2 Ab (clone SP3) at a dilution of 1:50, at 37°C for 32
min, and developed with a proprietary Ventana amplifica-
tion reagent kit followed by DAB chromogen. Finally, sec-
tions were counterstained with hematoxylin and
mounted. HER2 was scored visually according to the
ASCO/CAP guidelines [38]: 0 or 1+ (negative): no stain-
ing or incomplete membrane staining in > 30% of tumor
cells; 2+ (weakly positive, equivocal): strong, complete
membranous staining in < 30% cells or weak to moderate
heterogeneous staining in > 10% cells); 3+ (strongly pos-
itive: strong complete membrane staining in > 30% of
tumor cells). All cases were reviewed and scored by one
pathologist (CBG). Tissue cores that were missing, or were
otherwise uninterpretable were not included in the analy-
sis.
Fluorescence in situ hybridization
Six-micron sections of the TMA slides were hybridized
with probes to LSI® Her-2/neu and CEP® 17 with the Path-
Vysion™ HER-2 DNA Probe Kit using a modified protocol.
Briefly, slides were baked overnight at 60°C, deparaffin-
ized and dehydrated. Pre-treatment washes included 10
mM citric acid buffer (pH 6.0) (80°C, 45 minutes), 2×
SSC twice (5 minutes each), distilled water (1 minute).
Slides were protease treated at 37°C for 12 minutes,
washed with 2×SSC twice (5 minutes each), dehydrated
and air-dried, then counterstained with DAPI and visual-
ized on a Zeiss Axioplan epifluorescent microscope. Anal-
ysis of FISH signals was performed using MetasystemsTM
automated image acquisition and analysis system,
Metafer (Metasystems, Altlussheim, Germany). This FDA-
approved, automated system scores FISH signals by
employing specific measurement algorithms to detect and
quantify clustered signals. A high correlation between
manual and automated scoring of FISH signals has been
previously reported [39]. Average copy number for each
probe was calculated and the amplification ratio (ratio
between the average copy per cell for HER2 and the aver-
age copy for centromere 17) determined. Amplification
ratios > 2.2 are considered positive [38]. Tumors that
failed to hybridize were not included in the analysis.
Statistical analysis
Tests for heterogeneity were performed for the parame-
ters: age, stage, grade, residual disease, exposure to previ-
ous chemotherapy, and the mean follow-up time with
regard to both progression and overall survival for the
HER2 positive and HER2 negative cohorts utilizing the
Welch ANOVA, or the Pearson χ2 statistic as appropriate.
Progression free survival (PFS) is defined as the time from
surgery to the first clinical evidence of recurrence ("chem-
ical" recurrences i.e., tumor marker elevations not
included). Overall survival (OS) time is defined as the
time from surgery until death from any cause, or until the
last date of follow-up. Kaplan-Meier survival analyses and
the log-rank test were used to assess the impact of various
clinicopathologic parameters and HER2 amplification on
PFS and OS time.
Results
Immunostaining and FISH data were available for 33
cases of mucinous carcinoma and 16 cases of mucinous
BOT (Figure 1). Loss of cases from the original pool of 40
carcinomas was primarily due to use of tissue microarrays
where small sample size with few tumor cells or loss of tis-
sue after digestion result in inability to assess amplifica-
tion [39]. Demographic and clinicopathologic data for the
mucinous carcinomas with and without HER2 amplifica-
tion are shown in Table 1. Tumor grade was the only
parameter shown to be associated with progression free
(PFS) (p < 0.001) and overall survival (OS) time (p <
0.001). HER2 overexpression by IHC was seen in five of
the carcinomas (3+ in four cases, 2+ in one case). There
was high-level HER2 amplification (HER2/CEP17 ratios >
5) in six cancer cases (6/33 = 18.2%), including the five
cases with HER2 overexpression. However, one case had
discordant IHC and FISH results (IHC score of 0, FISH
HER2/CEP ratio of 6.7) (Table 2). Of sixteen mucinous
borderline tumors, three (3/16 = 18.8%) demonstrated
HER2 amplification (HER2/CEP17 ratios of 3.1-3.3). One
case of BOT showed discordant results with an IHC score
of 0 and HER2/CEP ratio of 2.4 (Table 3).
We then looked at any recurrences with tissue available
for FISH and IHC, to determine if HER2 expression levels/
copy number changed in the recurrence. Seven patients
whose tumor was represented on the TMA and all three of
the cases from the previously published case series [33]
developed recurrent disease. None of these 10 cases that
recurred had initial HER2 amplification. Tissue specimens
were available for testing in 2/10 recurrences, neither of
which demonstrated HER2 immunoreactivity or amplifi-
cation (HER2 amplification ratio of 1.2 and 0.77, respec-
tively). Among the cases represented on the TMA, there
were no recurrences in the six patients with HER2 ampli-
fication, and seven recurrences in the 27 cases where
HER2 was not amplified. There was no significant differ-
ence in prognosis associated with HER2 amplification at
the time of diagnosis (pLog-Rank p = 0.0920; (Figure 2).
Of the three cases of recurrent mucinous carcinoma iden-
tified prospectively, all showed strong HER2 expression
and amplification at the time of recurrence and were
treated with a combination of conventional chemother-
apy and trastuzumab. These cases are described in detail
below.BMC Cancer 2009, 9:433 http://www.biomedcentral.com/1471-2407/9/433
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Case 1
The first patient with recurrent mucinous carcinoma ini-
tially presented at age 19 with irregular periods, pelvic
pain, increased abdominal girth, and an elevated CA125
of 110 kU/L (other markers normal). Imaging revealed a
15 cm mass and ascites. She underwent surgical staging
including unilateral salpingoophorectomy (USO), appen-
dectomy, omentectomy, peritoneal biopsies, and wash-
ings. Pathology reported a 20 × 15 × 14 cm mucinous
BOT, intestinal type with focal inatraepithelial carcinoma
of the ovary, all other specimens negative, stage Ia. She
was observed and did well until 15 months later when she
was noted to have an elevation in her CA125 to 81 kU/L.
A CT scan revealed ascites and a mass in the contralateral
ovary. She underwent USO and multiple biopsies. Pathol-
ogy showed a mucinous borderline tumor of the ovary
with intraepithelial carcinoma, but there were now
implants of invasive mucinous carcinoma on the perito-
neal surfaces. She received carboplatin and paclitaxel (CP)
for six cycles, with normal CA125 throughout but again
recurred four months after completion of therapy, based
on reaccumulation of ascites, omental disease, elevated
CA125 (130 kU/L), and abdominal symptoms. Pathology
review of her first recurrence was performed to assess for
molecular markers. This revealed the overexpression and
amplification of HER2 (IHC 3+, HER2/CEP ratio 7.2)
(Figure 3) and trastuzumab (6 mg/kg) was given in addi-
tion to single agent monthly carboplatin (600 mg/m2). A
dramatic response, based on imaging and tumor markers,
was noted after three cycles (Figure 4) and she completed
a total of six cycles of this combination. She then received
trastuzumab alone for three cycles with stable disease after
which her markers began to rise and ascites and omental
disease were seen on CT scan. Carboplatin was reintro-
duced but her markers continued to increase and she was
changed to gemcitabine in combination with trastuzu-
mab. Her CA125 level dropped from 1800 to 180 kU/L
after the first cycle but she developed signs and symptoms
of large bowel obstruction. She was taken to surgery for
necrotic tumor in her cecum and splenic flexure and
underwent a hemicolectomy and debulking without com-
plications. She continued on gemcitabine and trastu-
zamab for six cycles with stable markers (CA125 range 50-
210 kU/L). She progressed and failed three other tradi-
tional chemotherapy agents (capecitabine, liposomal
doxorubicin, and etoposide) before ultimately succumb-
ing to her disease. She died 50 months from time of diag-
nosis secondary to respiratory distress with massive
intractable pleural effusions and pulmonary emboli.
Case 2
The second patient was a 33yo taken to the operating
room for a 10 cm mass suspected to be benign. There was
intra operative rupture of thick mucus within the abdom-
Table 1: Demographics and clinicopathologic parameters for the 33 mucinous ovarian carcinoma cases identified retrospectively.
Parameter HER2+ HER2- p-value
Age (years) 48.0 (31-72) 51.4 (18-76) 0.62a
Stage I 67% (N = 4) 67% (N = 18) 0.88b
II 33% (N = 2) 29% (N = 8)
III 0% (N = 0) 4% (N = 1)
Grade 1 50% (N = 3) 30% (N = 8) 0.55b
2 50% (N = 3) 63% (N = 17)
3 0% (N = 0) 7% (N = 2)
Residual Disease No 100% (N = 6) 100% (N = 27) NR
Prior Chemotherapy No 100% (N = 6) 100% (N = 27) NR
Mean Progression Free Survival (years) 7.90 (3.20 -- 11.35) 5.15 (0.17 -- 20.4) 0.12a
Mean Overall Survival (years) 7.90 (3.20 -- 11.35) 5.43 (0.35 -- 20.4) 0.16a
Progression free survival (PFS) is defined as the time from surgery to the first clinical evidence of recurrence. Overall survival (OS) is defined as the 
time from surgery until death from any cause, or until the date of last follow-up. All times are given in years
a Comparisons across HER2 status computed with the Welch ANOVA test
b Comparisons across HER2 status computed with the Pearson Chi Square Statistic
NR Not reported due to equivalenceBMC Cancer 2009, 9:433 http://www.biomedcentral.com/1471-2407/9/433
Page 5 of 12
(page number not for citation purposes)
Table 2: Immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) results for HER2 protein expression and gene 
amplification respectively with amplification (in bold) observed in 6/33 (18.2%) mucinous carcinomas.
ID IHC (HER2) HER2/CEP 17 Ratio Patient Outcome IHC/FISH concordance
V1 0 0.8
V2 3 8.0
V3 0 1.0
V4 0 1.1
V5 3 5+
V6 3 5.5
V7 0 1.1
V8 1 1.9
V9 0 1.2
V10 0 6.7 Discordant
V11 0 1.0
V12 0 0.7
V13 0 1.0
V14 0 0.9 Recurrent
V15 0 1.1
V16 0 1.1
V17 0 1.4 Recurrent
V18 0 1.3 Recurrent
V19 1 0.8 Recurrent
V20 2 6.2
V21 0 1.5 Recurrent
V22 0 1.2
V23 0 1.2
V24 0 1.7 Recurrent
V25 0 1.1
V26 0 0.9
V27 0 1.0 RecurrentBMC Cancer 2009, 9:433 http://www.biomedcentral.com/1471-2407/9/433
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inal cavity. RSO and washings were performed. Final
pathology revealed a FIGO grade 2 invasive mucinous car-
cinoma with destructive stromal invasion, and normal fal-
lopian tube. She was fully staged (USO, appendectomy,
biopsies, washings) at a second procedure one month
later, with all specimens negative, Stage Ic. She received
three cycles of CP followed by pelvic and whole abdomi-
nal radiation. She recurred 40 months later with a large
pulmonary metastasis and subcarinal lymphadenopathy.
She was initially deemed unresectable and received CP for
four cycles and achieved a partial remission. The CA 19-9
had also decreased from a high of 1000 kU/L to 80 kU/L
pre-thoracotomy. She underwent right middle and lower
lobectomy. Immunohistochemistry of her tumor at this
time revealed 3+ positivity for HER2 protein and a HER2/
CEP17 ratio of 7.5 (Figure 3). She was then changed to
trastuzumab monotherapy, which she took for a total of 5
cycles (6 mg/kg for three weeks) and remained without
clinical evidence of disease and with normal tumor mark-
ers. One month after the discontinuation of trastuzumab
V28 3 5.1
V29 1 1.3
V30 0 1.0
V31 0 1.2 Recurrent
V32 0 1.4 Recurrent
V33 0 1.0 Recurrent
Table 2: Immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) results for HER2 protein expression and gene 
amplification respectively with amplification (in bold) observed in 6/33 (18.2%) mucinous carcinomas. (Continued)
Table 3: Immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) results for HER2 protein expression and gene 
amplification respectively with amplification (in bold) observed in 3/16 (18.8%) mucinous borderline tumors of the ovary.
ID IHC (HER2) HER2/CEP 17 Ratio IHC/FISH concordance
VB1 0 0.9
VB2 0 0.8
VB3 0 0.8
VB4 1 1.2
VB5 0 1.2
VB6 0 1.0
J1 3 3.2
J2 0 0.8
J3 0 1.2
J4 0 1.1
J5 0 1.1
J6 0 1.2
J7 0 2.4 Discordant
J8 2 3.1
J9 0 1.3
J10 0 1.3BMC Cancer 2009, 9:433 http://www.biomedcentral.com/1471-2407/9/433
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therapy she began experiencing severe headaches, neck
spasms and vomiting. A CT scan of the head revealed mul-
tiple bilateral brain metastases (prior CT's of the head neg-
ative, within six months), predominantly in her frontal
lobes with possible interventricular extension. She was
given whole brain radiation, 2000 cGy prescribed to the
midplanes in five fractions. Despite radiation the patient
developed progressive intracranial tumor without evi-
dence of disease elsewhere. She died less than three
months after discovery of her brain metastases, 56
months from initial diagnosis.
In the third case, evaluation of her response to trastuzu-
mab alone and in combination with platin-based chemo-
therapy was not possible by RECIST criteria (not imaged
pre/post therapy and inconsistent tumor marker assess-
ment). Interestingly, evaluation of her primary presenta-
tion, first recurrence and second recurrence showed an
apparent change in HER2 amplification status. Careful re-
analysis of the primary tumor identified an area of tumor
heterogeneity. The primary tumor was predominantly
HER2 negative with only focal HER2 expression (Figure
5). The areas showing overexpression also showed HER2
amplification (data not shown). In the recurrent speci-
mens (28 and 57 months from initial diagnosis) there was
diffuse HER2 overexpression and amplification.
Discussion
Development of treatments for rare tumors is challenging.
The NCI State of the Science meeting on ovarian cancer in
2005 recognized the need for separate trials for ovarian
mucinous carcinoma, a rare subtype of EOC that responds
poorly to conventional chemotherapy [23,27]. An
increased understanding of the importance of histologic
subtype in EOC has resulted in an increased emphasis on
understanding the molecular changes leading to the
Flowchart outlining the process of case identification for our retrospective series of mucinous ovarian cancers and mucinous  borderline ovarian tumors Figure 1
Flowchart outlining the process of case identification for our retrospective series of mucinous ovarian cancers 
and mucinous borderline ovarian tumors.
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development of tumor subtypes with the goal of targeted
therapy specific to each subtype. Success with this strategy
is evident in breast cancer and there is increasing evidence
from preclinical models of gastroesophageal cancers that
HER2 can be targeted in this disease [28-30,32-34]. Muci-
nous EOC resembles adenocarcinoma of the gastro-
esophageal region and molecular targeted therapy may
also be indicated in appropriately selected cases of muci-
nous EOC.
Previously reported series investigating the prognostic
implications of HER2 overexpression or HER2 targeted
therapy in EOC included few or no cases of mucinous his-
tology [19-23,28]. Varying techniques have been used to
determine HER2 overexpression, often with less specific
IHC assays, no FISH correlation, and inconsistent scoring/
classification systems. Our series suggest that immunohis-
tochemistry, FISH, and a scoring system similar to that
used for breast cancer can be used for mucinous EOC and
that there is good correlation between IHC and FISH
results (2/49 or 4% discrepant, all with negative IHC and
positive FISH). The correct interpretation for these cases
with discordant IHC and FISH is not clear. The frequency
of HER2 overexpression/amplification is higher than pre-
viously reported (18%) and these cases are candidates for
molecular therapy
A dramatic response was observed in a patient with recur-
rent mucinous EOC showing amplification of HER2,
treated with trastuzumab in combination with traditional
chemotherapy after conventional therapy had ceased to
work. The second prospectively identified case with HER2
overexpression and amplification received trastuzumab
treatment, however she developed isolated intracranial
tumor metastasis, a rare site of metastatic tumor in EOC.
HER2 overexpression may provide tumor cells with
increased metastatic aggressiveness thereby increasing the
spread to sites such as the lungs and the central nervous
system [40]. In breast cancer patients, isolated central
Kaplan-Meier survival curves demonstrating that the pres- ence of HER2 amplification in primary mucinous carcinomas  is not of prognostic significance with respect to disease  recurrence Figure 2
Kaplan-Meier survival curves demonstrating that the 
presence of HER2 amplification in primary mucinous 
carcinomas is not of prognostic significance with 
respect to disease recurrence.
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HER2 immunostaining and FISH of tumors from cases 1 and 2 (Case 2-sample from lung), who subsequently received trastuzu- mab either alone or in combination with conventional chemotherapy Figure 3
HER2 immunostaining and FISH of tumors from cases 1 and 2 (Case 2-sample from lung), who subsequently 
received trastuzumab either alone or in combination with conventional chemotherapy. Each tumor shows strong 
immunoreactivity for HER2 and amplification by FISH (HER2 probe -- red, CEP17 probe -- green).
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Computed tomography images of Case 1 Figure 4
Computed tomography images of Case 1. The first image (a.) was taken four months after completion of (surgery and) 
chemotherapy treatment for her first recurrence. Imaging had been ordered for increased gastrointestinal symptoms and an 
elevation in her tumor markers. Ascites and omental disease are noted. Carboplatin and trastuzumab were commenced with a 
dramatic response (b. resolution of ascites and omental nodules) seen after only three cycles. Graphic representation of 
CA125 levels (c.) also demonstrates a drop in CA125 levels after the initiation of carboplatin and trastuzamab therapy and sta-
ble CA125 levels during trastuzamab monotherapy for at least three cycles.BMC Cancer 2009, 9:433 http://www.biomedcentral.com/1471-2407/9/433
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nervous system metastases have been observed in 9-10%
of patients receiving trastuzumab-based therapy [41]. The
development of central nervous system metastases in
these patients may occur due to increased patient survival
times (i.e., brain metastases may become symptomatic as
a result of an extended life span), and the inability of tras-
tuzumab to penetrate the blood-brain barrier [40]. We
postulate that this limitation in trastuzumab therapy
explains the isolated brain recurrence in this patient who
had complete resolution of her disease process in all other
locations.
The prognostic implications of HER2 amplification in
mucinous EOC or BOT have not been studied previously.
None of the cases with HER2 overexpression or amplifica-
tion identified in the retrospective case series experienced
a recurrence. Determination of HER2 status at the time of
diagnosis is unlikely to be a clinically relevant prognostic
indicator. We believe, however, that assessment of HER2
status can provide valuable information in patients with
advanced stage or recurrent mucinous EOC. For those
patients whose tumors demonstrate overexpression and
amplification of HER2, targeted therapy with trastuzumab
(+/- conventional chemotherapy) can be considered. As
seen in other cancers, HER2 heterogeneity was demon-
strated in one of our mucinous ovarian carcinomas and
repeat analysis of tumors of interest may be warranted.
Conclusion
Prior investigations suggest HER2 amplification does not
seem to be a significant event in epithelial ovarian cancers
when analyzed across all histologic subtypes. However,
we have demonstrated that in ovarian mucinous carcino-
mas HER2 amplification is relatively common (6/33,
18.2%), although not necessarily of prognostic signifi-
cance. Response to conventional therapy is limited in this
rare histologic subtype of EOC and trastuzumab therapy
provides a treatment option for patients with mucinous
carcinoma when the tumor has HER2 amplification and
overexpression.
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